Medpace Holdings, Inc. $MEDP Shares Bought by Boston Trust Walden Corp

Boston Trust Walden Corp lifted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 12.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 151,074 shares of the company’s stock after acquiring an additional 16,270 shares during the period. Boston Trust Walden Corp owned approximately 0.54% of Medpace worth $47,416,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. GAMMA Investing LLC increased its position in shares of Medpace by 37.1% in the first quarter. GAMMA Investing LLC now owns 307 shares of the company’s stock worth $94,000 after acquiring an additional 83 shares in the last quarter. Inspire Investing LLC purchased a new position in shares of Medpace in the first quarter valued at $2,059,000. Truist Financial Corp boosted its stake in shares of Medpace by 10.2% in the second quarter. Truist Financial Corp now owns 12,898 shares of the company’s stock valued at $4,048,000 after purchasing an additional 1,197 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Medpace by 10.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,182 shares of the company’s stock valued at $371,000 after purchasing an additional 111 shares during the period. Finally, Voya Investment Management LLC boosted its stake in shares of Medpace by 7.6% in the first quarter. Voya Investment Management LLC now owns 21,976 shares of the company’s stock valued at $6,696,000 after purchasing an additional 1,560 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on MEDP. Deutsche Bank Aktiengesellschaft upped their target price on shares of Medpace from $270.00 to $430.00 and gave the company a “hold” rating in a research note on Wednesday, July 23rd. Zacks Research downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 22nd. Weiss Ratings restated a “buy (b-)” rating on shares of Medpace in a research note on Wednesday, October 8th. Truist Financial increased their price objective on shares of Medpace from $298.00 to $436.00 and gave the company a “hold” rating in a research note on Wednesday, July 23rd. Finally, Jefferies Financial Group increased their price objective on shares of Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a research note on Tuesday, September 9th. Two research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Reduce” and a consensus price target of $424.10.

Insider Activity at Medpace

In other Medpace news, CFO Kevin M. Brady sold 12,000 shares of the stock in a transaction on Thursday, July 24th. The shares were sold at an average price of $454.23, for a total transaction of $5,450,760.00. Following the sale, the chief financial officer directly owned 6,000 shares of the company’s stock, valued at approximately $2,725,380. This represents a 66.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Susan E. Burwig sold 10,000 shares of the stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $480.00, for a total transaction of $4,800,000.00. Following the sale, the vice president directly owned 57,500 shares in the company, valued at $27,600,000. This trade represents a 14.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 161,266 shares of company stock valued at $74,111,427 in the last ninety days. 20.30% of the stock is owned by insiders.

Medpace Price Performance

NASDAQ MEDP opened at $516.93 on Wednesday. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $547.15. The company has a market capitalization of $14.52 billion, a price-to-earnings ratio of 38.43, a price-to-earnings-growth ratio of 3.31 and a beta of 1.40. The company’s fifty day moving average price is $486.83 and its two-hundred day moving average price is $377.81.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating analysts’ consensus estimates of $3.00 by $0.10. The firm had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The firm’s revenue was up 14.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.75 EPS. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.